SERO Serologicals (MM)

Serologicals Corporation (NASDAQ: SERO) announced today that it has completed its previously announced acquisition of Cytomyx Ltd., a wholly owned subsidiary of Cytomyx Holdings Plc (AIM: CYX). Based in Cambridge, U.K., Cytomyx Ltd. is a leading provider of ion channel cell lines and drug discovery services. With 23 distinct ion channel cell lines commercially available, and more in its pipeline, Cytomyx Ltd. offers the largest portfolio of distinct ion channel cell lines in the marketplace today. Serologicals paid U.S. $7 million for the stock of Cytomyx Ltd. "We are very pleased to announce the completion of the Cytomyx Ltd. acquisition," said David A. Dodd, President and CEO of Serologicals. "Ion channels represent the third largest target class for Biopharma research and drug development today. The expertise that Cytomyx Ltd. brings will greatly enhance our drug discovery products and services portfolio with therapeutically relevant ion channel cell lines and ion channel screening services. With GPCRs, kinases, and ion channels, Serologicals will better serve the needs of our Biopharma customers through a comprehensive portfolio offering." Additional details about the acquisition and Cytomyx Ltd. business can be found in the Company's March 14, 2006 press release (www.serologicals.com) in which the signing of the acquisition agreement was announced. Serologicals Corporation, headquartered in Atlanta, Georgia, is a global provider of biological products and enabling technologies, which are essential for the research, development and manufacturing of biologically based life science products. The Company's products and technologies are used in a wide variety of innovative applications within the areas of oncology, hematology, immunology, cardiology and infectious diseases, as well as in the study of molecular biology. Serologicals has approximately 1,000 employees worldwide, and its shares are traded on the NASDAQ national stock market under the symbol SERO. For information on Serologicals Corporation, visit the company's corporate website at www.serologicals.com. This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result," "are expected to," "we anticipate," "we estimate," "we project" or similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made, and Serologicals undertakes no obligation to update these statements based on events that may occur after the date of this press release.